Capsovision, Inc (CV)
AI stock analysis · as of Jul 10, 2026
Loading microstructure…
CapsoVision is a micro-cap ($288M) single-product medical device company selling the CapsoCam Plus small-bowel capsule endoscope, with $13.6M in 2025 revenue growing 15% YoY but burning ~$23M in free cash flow and carrying a going-concern qualification. The core investment question is whether management can bridge a multi-year revenue gap—following the FDA setback that pushed CapsoCam Colon revenue to mid-2027—via dilutive financings long enough to reach a much larger colon-screening market, or whether liquidity strain and single-product concentration impair equity holders first.
valuationExpensive on absolute multiples (P/S 21x, P/B 14x) but this is really an option value on regulatory catalysts—traditional multiples don't apply given negative EBITDA and going-concern status; framed as an event-driven small-cap, the risk/reward hinges on financing terms, not current fundamentals.
This analysis is from Jul 10, 2026. Want the latest on CV, plus the ability to generate fresh research on demand?
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.
Bull case
- · Consistent volume-led growth: revenue up every year since 2020 U.S. direct-sales launch, +15% in 2025 to $13.6M, with gross margin holding above 52%
- · Multiple pipeline catalysts: AI-pathology 510(k) targeted mid-2026, capsule delivery device Q4 2026, CapsoCam Colon second-gen 510(k) Q3 2026, plus esophageal varices and pancreatic cancer studies expanding TAM
- · Insider conviction: a 10% owner made a ~$102K open-market purchase, insiders hold 32% of shares, and 180-day net insider selling is $0—no signs of insider distribution
- · Recent capital infusion: March 2026 private placement (~$14M reported in news) extends runway to execute on 2026 regulatory milestones
- · Optionality on a $311M global colon-capsule market by 2030 if second-gen CapsoCam Colon clears; also expanding via pediatric indication (cleared Dec 2024) and telemedicine at-home ingestion clearance
- · Elevated short ratio of 13.76 days-to-cover on 3.9% of float creates squeeze potential on any positive regulatory or clinical update
Bear case
- · Going-concern qualification from auditors in both 2024 and 2025—the most serious red flag on the filing—implies further dilution is essentially required
- · Free cash flow of -$22.9M against only $10.1M cash means the balance sheet is structurally short of a full year of burn absent the March 2026 raise
- · Single-product concentration: 100% of revenue from CapsoCam Plus, plus a material customer concentration disclosed but unquantified
- · CapsoCam Colon FDA setback in Dec 2025 pushes the biggest revenue catalyst to mid-2027, leaving a multi-year gap during which the story is essentially 'don't run out of cash'
- · Valuation is rich for a distressed micro-cap: 21x price/sales and 14x price/book against negative operating margin (-254%) and ROE of -185%
- · Single-source Taiwan/Japan supply chain for critical components exposes the company to tariff and geopolitical disruption
- · Reimbursement dependency: any Medicare or payor rate compression would immediately hit adoption and revenue
Catalysts
- · Next earnings 2026-08-13 — watch revenue trajectory and cash runway commentary
- · AI-assisted pathology detection 510(k) clearance targeted mid-2026
- · CapsoCam Colon second-gen 510(k) submission Q3 2026
- · Capsule delivery device launch expected Q4 2026 (opens pediatric and dysphagia populations)
- · Pancreatic cancer feasibility study readout Q2 2026
- · Potential short squeeze given 13.76 days-to-cover if a positive regulatory or clinical catalyst hits
Key risks
- · Dilution risk from going-concern status and ongoing ~$23M annual burn against ~$10M cash
- · Further FDA delay or rejection on the CapsoCam Colon second-gen submission, extending the revenue gap beyond mid-2027
- · Loss of the material single customer disclosed in the 10-K would meaningfully impair 2026 revenue
- · Supply-chain interruption from single-source Taiwan/Japan vendors
- · Reimbursement rate cuts by CMS or private payors reducing physician economics
- · Thin sell-side coverage (1 analyst) and low institutional ownership (8.1%) mean liquidity and price discovery are poor
What to watch
- · Q2 2026 earnings on 2026-08-13—cash balance, burn rate, and any commentary on customer concentration
- · AI-pathology 510(k) decision expected mid-2026
- · CapsoCam Colon second-gen 510(k) submission in Q3 2026
- · Any 8-K disclosures on new equity raises or terms of the March 2026 private placement
- · 52-week low of $3.43 as key technical support; 52-week high of $15.37 as upside reference
- · Short interest trend given 13.76 days-to-cover—rising short interest into a catalyst amplifies squeeze potential
Key metrics
Price target rationale
Base case $6.50 assumes modest revenue growth to ~$16M in 2026 at ~15x P/S with a dilutive raise offsetting operational progress. Bull case $12 aligns near the street target and reflects positive AI 510(k) clearance and successful CapsoCam Colon second-gen submission driving multiple expansion. Bear case $2 assumes a heavily dilutive going-concern raise or additional FDA delay, pushing shares toward the 52-week low of $3.43 and below.
On Wall Street's view (mixed): The lone $10 sell-side target implies ~73% upside and is plausible on a favorable regulatory path, but with only one analyst covering the name and a going-concern flag, we view it as an aspirational bull-case number rather than a base case—we'd sit below the street.
Latest filing (10-K)
CapsoVision is a single-product GI capsule endoscopy company growing at 15% on $13.6M in revenue, but it carries a going-concern warning and its colon cancer screening capsule just hit a major FDA regulatory setback, pushing the next revenue catalyst to mid-2027 at the earliest.
CapsoVision (Nasdaq: CV) is a commercial-stage medical technology company that develops and sells capsule endoscopy systems for diagnosing GI-tract abnormalities. Its sole commercial product, CapsoCam Plus, is a single-use ingestible capsule with a 360-degree panoramic camera that stores video onboard and transmits it to a cloud platform (CapsoCloud) or local software (CapsoView) for physician review. The company sells primarily to gastroenterologists in the U.S. via a direct sales force and internationally through distributors, generating revenue from capsule unit sales and related services.
What the news says · bullish
The dominant storyline for CapsoVision (CV) centers on a cluster of positive corporate developments: a meaningful insider purchase by a 10% owner (~$102K), a board addition of a capsule endoscopy pioneer, an RSU vesting by a director, a fresh $14M capital raise to fund AI and capsule scope initiatives, and the launch of a pancreatic cancer study. These signals collectively suggest management and insiders have conviction in the company's direction. However, Q1 sales were flat, and the stock is a small, thinly covered name, so enthusiasm should be tempered. A significant portion of the news items in this feed relate to unrelated Mexican-listed companies (VIST, CEMEX, Aeromexico, FEMSA, etc.) sharing the 'CV' or 'S.A.B. de C.V.' label, which dilutes the signal and underscores how sparse pure-play CV coverage remains.
This analysis is from Jul 10, 2026. Markets move. Get the current read on CV and generate fresh AI research on any ticker.
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.